AstraZeneca (NYSE: AZN) is set to report Q2 earnings on Monday, and while the failure of the CARDIO-TTRansform trial for ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE